Evvy, a precision medicine company focused on the vaginal microbiome, has raised an oversubscribed $40 million series B round.
Evvy makes an at-home vaginal health test whose results are clinician-reviewed and offers personalized treatment plans. The round was led by Catalio Capital Management, alongside Rethink Impact, Muse Capital and Alumni Ventures, LabCorp Venture Fund, General Catalyst and others.
Evvy will lean on the capital as it pursues clinical validation of its AI-powered diagnostic and care models across women's health, starting with fertility, and expand distribution of Evvy through physician and partner channels.
“Our interest is in [exploring] biomarkers in the female body that we’ve underleveraged, that can help us understand women’s health outcomes,” Priyanka Jain, co-founder and CEO of Evvy, told Fierce Healthcare.
Since its founding in 2021, Evvy has amassed what it says is the world’s largest private clinical-grade dataset on the vaginal microbiome. This dataset informs Evvy’s peer-reviewed research, including the identification of six new bacterial vaginosis (BV) subtypes and hundreds of previously uncatalogued vaginal microbiome genomes.
“I do not want to wait for the government to fund women’s health research and especially vagina research,” Jain noted. “We have forever defined health and disease based on middle-aged, midsized white men.”
As of 2025, Evvy has led a fertility study in partnership with IVF clinics at US Fertility, with findings to be published later this year. The prospective study takes samples from patients going through IVF to evaluate their vaginal microbiome and determine whether there is a way to predict outcomes.
"We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it," Jacob Vogelstein, co-founder and managing partner at Catalio Capital, said in an announcement. "Its combination of proprietary data, clinical evidence and a growing biomarker discovery engine creates an entirely new foundation for precision women's healthcare. We believe Evvy is building the data platform that will define this category for decades to come."
Most patients come to Evvy with active vaginal symptoms or fertility challenges that the traditional system has failed to address. In the U.S., vaginal symptoms are a leading reason women seek healthcare, yet misdiagnosis rates are high, Jain said. They may try to self-treat with over-the-counter products, even though they may be incorrect about their condition. Evvy allows for a much more targeted answer.
Evvy has supported over 100,000 patients and 3,000 practitioners to date with its platform. The company is both DTC and B2B, working directly with patients or partnering with clinics and platforms like Carrot and Parsley. Patients can either take a sample for the Evvy test in a clinic or at home. Evvy has a provider-facing portal for ordering the test, receiving the results and talking to the Evvy clinical team. (In most cases, the patient is billed for the test regardless of where it is ordered, though it is included at some concierge medicine practices.)
“Everywere that women are going to get answers on their body, Evvy should be there,” Jain said.
The company’s one-time vaginal health test costs $159, with discounts if a patient subscribes to receive the test every three months. Jain says Evvy is working on obtaining insurance reimbursement.
In addition to its core offering, the company rolled out EvvyAI earlier this year, recognizing that patients often turn to chatbots for answers, yet today's leading AI models fail on 60% of women's health questions. Though it already offered free health coaching to anyone who takes its test, Evvy found that not everyone took advantage of the phone channel.
“A lot of patients would still not want to talk to someone live and would want to write in,” Jain said. EvvyAI is available to all Evvy users through a conversational interface. Escalation to a human is available as needed.
Jain’s own background is in data and machine learning. She is shocked by how little data there are in women’s healthcare. “We see ourselves as an onramp for data-driven, personalized healthcare,” she said. “Sometimes if you have a pretty brand and a good experience, people lump everything together. And I really believe women deserve more than wellness and cosmetic care.”